Anifrolumab

Generic name: Anifrolumab
Brand names: Saphnelo
Dosage form: intravenous solution (fnia 300 mg/2 mL)
Drug class: Selective immunosuppressants

Usage of Anifrolumab

Anifrolumab is used to treat moderate to severe systemic lupus erythematosus (SLE) in adults who already receive standard treatment for SLE.

Anifrolumab may also be used for purposes not listed in this medication guide.

Anifrolumab side effects

Get emergency medical help if you have signs of an allergic reaction: hives; feeling lightheaded; difficult breathing; swelling of your face, lips, tongue, or throat.

You may get infections more easily, even serious or fatal infections. Call your doctor right away if you have signs of infection such as:

fever, chills, sweats, muscle aches;

painful skin sores with warmth or redness;

urinating more, pain or burning when you urinate;

diarrhea, stomach pain; or

cough, shortness of breath.

Anifrolumab may cause serious side effects. Call your doctor at once if you have:

fever, chills, cough with mucus, chest pain, feeling short of breath; or

symptoms of herpes zoster (shingles)--skin sores or blisters, itching, tingling, burning pain, rash on your face or torso.

Common side effects of anifrolumab may include:

shingles;

cough, trouble breathing;

cold symptoms such as stuffy nose, sneezing, sore throat; or

headache, tiredness, dizziness, or nausea when the medicine is injected.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Before taking Anifrolumab

You should not be treated with anifrolumab if you are allergic to it.

Tell your doctor if you have ever had:

an active or chronic infection;

cancer;

treatment with a biologic medicine or monoclonal antibody; or

if you are scheduled to receive a vaccine.

Make sure you are current on all vaccines before you start using anifrolumab.

Tell your doctor if you are pregnant or you become pregnant, or if you are breastfeeding.

If you are pregnant, your name may be listed on a pregnancy registry to track the effects of anifrolumab on the baby.

Anifrolumab may affect your baby's immune system, but having SLE during pregnancy may cause complications such as worsened lupus, eclampsia (dangerously high blood pressure), premature birth, miscarriage, or growth problems in the unborn baby. SLE in the mother may also cause lupus or heart problems to develop in the newborn. The benefit of treating SLE may outweigh any risks to the baby.

Not approved for use by anyone younger than 18 years old.

Relate drugs

How to use Anifrolumab

Usual Adult Dose for Systemic Lupus Erythematosus:

300 mg IV over 30 minutes every 4 weeks Comment:-The efficacy of this drug has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus, therefore, the use in these situations is not recommended.Uses: -For the treatment of adult patients with moderate to severe systemic lupus erythematosus (SLE), who are receiving standard therapy

Warnings

Use only as directed. Tell your doctor if you use other medicines or have other medical conditions or allergies.

What other drugs will affect Anifrolumab

Other drugs may affect anifrolumab, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use.

Popular FAQ

Saphnelo starts to block interferon receptors as soon as it is administered, but it may take about 3 to 6 months of regular monthly injections before you notice the full effects of the medication and noticeable symptom relief. The endpoint of most trials was an improvement in disease activity after 52 weeks which was significantly improved in 62% to 100% of trial participants, depending on the trial.

A Saphnelo infusion takes about 30 minutes to administer. The medicine is diluted into an infusion bag by your healthcare provider, and while you are seated, the infusion mixture will run into your vein through a needle (this is called an intravenous infusion). A Saphnelo infusion is usually given at doctor’s office, a hospital, or an infusion center.

Benlysta and Saphnelo are both targeted treatments, but they target different parts of the immune system that are particularly overactive in lupus. Benlysta targets and blocks the activity of a type of white blood cell called a B cell, which produces antibodies that attack tissue, causing symptoms of SLE. It is classified as a B-lymphocyte stimulator (BLyS)-specific inhibitor. Saphnelo targets the type I interferon receptor and inhibits the activity of type 1 interferons. Activation of the interferon system is a common underlying characteristic of SLE that leads to the immune system being constantly “switched on”, contributing to SLE symptoms. Saphnelo is classified as a type 1 interferon receptor antagonist. Benlysta was first approved in 2011 and Saphnelo was approved in 2021. Continue reading

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.